3Jeon YK,Kim MR,Huh JE,et al.Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes[J].J Korean Med Sci,2011,26(2):258.
4KDOQI.KDOQI clinical practice guidelines and clinical practice Recommendations for diabetes and chronic kidney disease[J].Am J Kidney Dis,2007,49(2 Suppl 2):S152.
5Blouza S,Dakhli S,Abid H,et al.Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy[J].J Nephrol,2010,23(4):415.
6Lewis EJ,Lewis JB,Greene T,et al.Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria:A randomized controlled trial[J].Am J Kidney Dis,2011,58(5):729.
7Broekhuizen LN,Lemkes BA,Mooij HL,et al.Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus[J].Diabetologia,2010,53(12):2 646.
8Cooke JP. The endothelium:a new target for therapy [J]. Vasc Meal,2000,5(1) ..49-53.
9Craiem D, Chimni G,Simon A, et al. New assessment of endothelium-dependent flow-mediated vasodilation to characterize endothelium dysfunction [J]. Am J Ther, 2008,15(4) ,340-344.
10Motoyama T,Kawano H, kuqivama K, et al. Vitamin E dministmtion improves impairment of endothelium-de pendent vasodilation in patients with coronary spastic angina[J].J Am Coil Cardiol, 1998,32(6) : 1672- 1679.
